Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

The research team led by Dr. Moon-Hyeong Seo from the Natural Product Drug Development Center at the Korea Institute of ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

Although intravitreal faricimab helped to decrease central subfield thickness (CST) in patients with eyes previously treated ...